Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tamsulosin
Drug ID BADD_D02113
Description Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
Indications and Usage Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)
Marketing Status Prescription
ATC Code G04CA02
DrugBank ID DB00706
KEGG ID D08560
MeSH ID D000077409
PubChem ID 60147
TTD Drug ID D05MBZ
NDC Product Code Not Available
Synonyms Tamsulosin | LY 253352 | LY-253352 | Tamsulosin Hydrochloride | 5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide | Flomax | YM 617 | YM-617
Chemical Information
Molecular Formula C20H28N2O5S
CAS Registry Number 106138-88-9
SMILES CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pyrexia08.05.02.0030.000325%
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.000093%Not Available
Renal disorder20.01.02.0020.000139%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000024%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000024%
Retrograde ejaculation21.03.01.006--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.02.05.0100.000093%
Sedation17.02.04.0050.000093%Not Available
Seizure17.12.03.0010.000232%
Shock24.06.02.002--Not Available
Sinus congestion22.04.06.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Sleep disorder19.02.04.0010.000093%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.03.020; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Swelling face23.04.01.018; 10.01.05.0180.000139%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000418%
Tachycardia02.03.02.0070.000093%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000093%Not Available
Tooth disorder07.09.05.001--Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000024%
Urinary retention20.02.02.0110.000279%
Urinary tract infection20.08.02.001; 11.01.14.0040.000093%
Urine flow decreased20.02.02.0120.000093%Not Available
Urticaria23.04.02.001; 10.01.06.001--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages